eif2 physiological vs pathological hypertrophy

In fact, there is almost a threefold increase in cardiac myocyte diameter in humans during development from infants toĪdults ( Hudlicka and Brown 1996). Myocytes withdraw from the cell cycle soon after birth, and subsequent growth of the heart during postnatal development isĪchieved predominantly through hypertrophy rather than hyperplasia of individual myocytes ( Pasumarthi and Field 2002 Olson and Schneider 2003). Growth of the heart during embryonic development occurs primarily through proliferation of cardiac myocytes. To the development of physiological/pathological hypertrophy and heart failure will also be discussed. On the regulation of cardiac growth, contractile function, and coronary angiogenesis. In this review we will discuss the role of the Akt signaling pathway in the heart, focusing

Stimuli in a phosphatidylinositol-3 kinase-dependent manner and regulates multiple aspects of cellular functions including The serine/threonine protein kinase Akt is activated by various extracellular These two types of hypertrophy are morphologically,įunctionally, and molecularly distinct from each other. Valvular heart diseases is called maladaptive or pathological hypertrophy. Cardiac growth observed inĪthletes represents adaptive or physiological hypertrophy, whereas cardiac growth observed in patients with hypertension or Postnatal growth of the heart is primarily achieved through hypertrophy of individual myocytes.

Eif2 physiological vs pathological hypertrophy